外科肿瘤学
乳腺癌
医学
遗传倾向
肿瘤科
内科学
癌症
妇科
疾病
作者
Marek Szwiec,Joanna Tomiczek‐Szwiec,Wojciech Kluźniak,Dominika Wokołorczyk,Karolina Osowiecka,Robert Sibilski,Małgorzata Wachowiak,Jacek Gronwald,Helena Gronwald,Jan Lubiński,Cezary Cybulski,Steven A. Narod,Tomasz Huzarski
出处
期刊:BMC Cancer
[Springer Nature]
日期:2021-08-30
卷期号:21 (1)
被引量:11
标识
DOI:10.1186/s12885-021-08718-3
摘要
Abstract Background Breast cancer in men accounts for fewer than 1 % of all breast cancer cases diagnosed in men and women. Genes which predispose to male breast cancer include BRCA1 and BRCA2. The role of other genes is less clear. In Poland, 20 founder mutations in BRCA1 , BRCA2 , CHEK2 , PALB2 , NBN , RECQL are responsible for the majority of hereditary breast cancer cases in women, but the utility this genes panel has not been tested in men. Methods We estimated the prevalence of 20 alleles in six genes ( BRCA1 , BRCA2 , CHEK2 , PALB2 , NBN , RECQL) in 165 Polish male breast cancer patients. We compared the frequency of selected variants in male breast cancer cases and controls. Results One of the 20 mutations was seen in 22 of 165 cases (13.3%). Only one BRCA1 mutation and two BRCA2 mutations were found. We observed statistically significant associations for PALB2 and CHEK2 truncating mutations. A PALB2 mutation was detected in four cases (OR = 11.66; p < 0.001). A CHEK2 truncating mutation was detected in five cases (OR = 2.93; p = 0.02). Conclusion In conclusion, we recommend that a molecular test for BRCA1, BRCA2, PALB2 and CHEK2 recurrent mutations should be offered to male breast cancer patients in Poland.
科研通智能强力驱动
Strongly Powered by AbleSci AI